Hemogenyx Pharmaceuticals plc

(“Hemogenyx Pharmaceuticals” or the “Company”)

 

Further re. Grant of Options

 

On 21 August 2020, the Company announced that the Directors had granted the Company’s co-founder and CEO Dr Vladislav Sandler options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company (“Share Options”). The Directors have now resolved to adjust the exercise price of the Share Options to 9p to reflect the Company’s share price at the time of the grant. All other details regarding the grant of the Share Options remain the same.
 

Enquiries:

Hemogenyx Pharmaceuticals plc	hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them (“PCA”):

1.	Details of PDMR/person closely associated with them
a)	Name	Dr Vladislav Sandler
b)	Position/status	CEO, Executive Director
c)	Initial notification/ amendment	Amendment to prior notification no. 00117904
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.09 5,000,000
d)	Aggregated information –     Aggregated volume –     Price	Price(s) Volume(s) N/A – variable 5,000,000
e)	Date of the transaction	20/08/2020
f)	Place of the transaction	Outside of a trading venue